# 羅氏執行長Thomas Schinecker指出「令人震驚」的官僚體制是主要障礙。

*biotech · news · 2026-04-23 · Devdiscourse*

## Key points

- 羅氏執行長Thomas Schinecker警告歐洲製藥業有落後美國和中國的風險。
- Schinecker指出歐洲過度的官僚體制是製藥創新的重大障礙。
- 美國將藥價與較便宜的外國替代品掛鉤的政策影響歐洲藥品上市策略。
- 羅氏與賽諾菲持續承諾歐洲市場，並在監管挑戰中積極協商定價。

Europe's pharmaceutical industry is under strain as it risks trailing the U.S. and China, warned Roche CEO Thomas Schinecker, citing 'mind-blowing' bureaucracy as a major hurdle. This warning follows U.S. President Trump's policy linking American drug prices to cheaper alternatives abroad, significantly affecting European launches. Despite acknowledging the challenges, industry leaders from Roche and Sanofi emphasize their commitment to introducing new drugs in Europe, negotiating pricing strategies to sustain innovation and market access. (With inputs from agencies.)

**Companies:** Roche, Sanofi
**Countries:** Switzerland, France, United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/business/3884466-europes-pharma-industry-faces-challenges-amid-global-competition)

---

Canonical: https://newsio.io/zh-TW/n/a9faa221-f896-48b8-964b-1506db7c23dc/thomas-schinecker
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works